Research graph
References from Spike antibody Fc is associated with protection from SARS-CoV-2 challenge in macaques. Local targets link to admitted publications; unresolved targets remain external evidence.
Evidence for antibody as a protective correlate for COVID-19 vaccines
10.1016/j.vaccine.2021.05.063 · 2021 · External reference
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
10.1038/s41591-021-01377-8 · 2021 · External reference
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
10.1038/s41541-023-00630-0 · 2023 · External reference
Towards a population-based threshold of protection for COVID-19 vaccines
10.1016/j.vaccine.2021.12.006 · 2022 · External reference
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
10.1126/science.abm3425 · 2022 · External reference
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
10.1016/j.vaccine.2021.06.057 · 2021 · External reference
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
10.1126/sciadv.abg7996 · 2021 · External reference
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
2020 · External reference
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
10.1038/s42003-021-02443-0 · 2021 · External reference
A systems biology approach to define SARS-CoV-2 correlates of protection
10.1038/s41541-025-01103-2 · 2025 · External reference
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
10.1038/s41577-022-00813-1 · 2023 · External reference
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with matrix-M vaccination
2021 · External reference
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
10.1016/j.celrep.2021.110114 · 2021 · External reference
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
10.1126/scitranslmed.abm7853 · 2026 · External reference
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
10.1126/sciimmunol.ade2798 · 2023 · External reference
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity
10.3389/fimmu.2021.737083 · 2021 · External reference
Anti-spike IgG4 and Fc effector responses: the impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting
2025 · External reference
Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines
2024 · External reference
Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment
10.4049/jimmunol.1200090 · 2012 · External reference
Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function
2019 · External reference
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
10.1126/science.abc8378 · 2021 · External reference
Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities
10.3389/fimmu.2017.00877 · 2017 · External reference
The role of Fc-FcγR interactions in IgG-mediated microbial neutralization
10.1084/jem.20151267 · 2015 · External reference
IgG binding characteristics of Rhesus macaque FcγR
10.4049/jimmunol.1502252 · 2016 · External reference
IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions
10.4049/jimmunol.177.6.3848 · 2006 · External reference
Biophysical and functional characterization of Rhesus macaque IgG subclasses
10.3389/fimmu.2016.00589 · 2016 · External reference
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
10.1126/science.aab3886 · 2015 · External reference
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV
10.1038/s41591-018-0161-0 · 2018 · External reference
IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs
10.1080/19420862.2016.1274845 · 2017 · External reference
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
10.1126/science.abc6284 · 2020 · External reference
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
2022 · External reference
Antibody-mediated NK cell activation as a correlate of immunity against influenza infection
10.1038/s41467-023-40699-8 · 2023 · External reference
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
10.1007/s00430-023-00773-w · 2023 · External reference
Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
10.1172/jci.insight.172470 · 2023 · External reference
Omicron variant spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines
10.1126/scitranslmed.abn9243 · 2022 · External reference
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
10.1038/s41590-023-01513-1 · 2023 · External reference
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
10.1038/s41467-023-39189-8 · 2023 · External reference
mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
10.1016/j.immuni.2022.01.001 · 2022 · External reference
Antibody effector functions are associated with protection from respiratory syncytial virus
10.1016/j.cell.2022.11.012 · 2022 · External reference
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
10.1016/j.celrep.2023.112326 · 2023 · External reference
Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia
10.5694/mja2.50569 · 2020 · External reference
SIMON an automated machine learning system, reveals immune signatures of influenza vaccine responses
10.4049/jimmunol.1900033 · 2019 · External reference
The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system
10.1038/s41597-019-0213-4 · 2019 · External reference
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
10.15252/msb.20209888 · 2020 · External reference
SIMON: open-source knowledge discovery platform
10.1016/j.patter.2020.100178 · 2021 · External reference
10.3389/frans.2022.1005558
10.3389/frans.2022.1005558 · External reference
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
10.1016/j.cell.2022.01.012 · 2022 · External reference
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
10.1038/s41467-022-28898-1 · 2022 · External reference
The classical complement pathway: activation and regulation of the first complement component
10.1016/s0065-2776(08)60340-5 · 1985 · External reference
Lectins as tools to select for glycosylated proteins
10.1007/978-1-61779-148-2_19 · 2011 · External reference
Variability of serum IgG sialylation and galactosylation degree in women with advanced endometriosis
10.1038/s41598-021-85200-x · 2021 · External reference
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals
10.1038/s41467-025-57947-8 · 2025 · External reference
Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: implications for protection and pathogenesis
10.3389/fimmu.2022.857481 · 2022 · External reference
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
10.1038/s41591-021-01540-1 · 2021 · External reference
Protection against SARS-CoV-2 omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
2023 · External reference
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
10.1038/s41591-022-01721-6 · 2022 · External reference
Correlates of protection against SARS-CoV-2 in rhesus macaques
10.1038/s41586-020-03041-6 · 2021 · External reference
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection
10.1126/sciimmunol.abo0226 · 2022 · External reference
From Rhesus macaque to human: structural evolutionary pathways for immunoglobulin G subclasses
10.1080/19420862.2019.1589852 · 2019 · External reference
Unresolved reference
2025 · External reference
Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement
10.1126/sciimmunol.aat7796 · 2018 · External reference
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
10.1172/jci82695 · 2015 · External reference
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
10.1182/blood-2008-09-179754 · 2009 · External reference
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength
10.4049/jimmunol.1003336 · 2011 · External reference
The COVID-19 cytokine storm; what we know so far
10.3389/fimmu.2020.01446 · 2020 · External reference
Cytokine storm in COVID-19: the current evidence and treatment strategies
2020 · External reference
Proinflammatory IgG Fc structures in patients with severe COVID-19
10.1038/s41590-020-00828-7 · 2021 · External reference
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
10.1038/s41467-021-21389-9 · 2021 · External reference
Alteration of rhesus macaque serum N-glycome during infection with the human parasitic filarial nematode Brugia malayi
10.1038/s41598-022-19964-1 · 2022 · External reference
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
10.1038/s41467-023-44211-0 · 2024 · External reference
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
10.1038/s41591-020-01179-4 · 2021 · External reference
Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens
10.1016/j.xpro.2022.101902 · 2022 · External reference
